6803-90-3 Usage
General Description
1-THIOPHEN-2-YLMETHYL-PIPERAZINE DIHYDROCHLORIDE is a chemical compound that consists of a piperazine core with a thiophenylmethyl substituent. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and medications. The dihydrochloride salt form of this compound is often chosen for its stability and solubility in aqueous solutions, making it suitable for use in pharmaceutical formulations. It has been studied for its potential therapeutic effects in the treatment of various neurological and psychiatric disorders, as well as for its potential use as a medication for other medical conditions. Overall, 1-THIOPHEN-2-YLMETHYL-PIPERAZINE DIHYDROCHLORIDE is a versatile chemical that has applications in both research and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 6803-90-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,8,0 and 3 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6803-90:
(6*6)+(5*8)+(4*0)+(3*3)+(2*9)+(1*0)=103
103 % 10 = 3
So 6803-90-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H14N2S/c1-2-9(12-7-1)8-11-5-3-10-4-6-11/h1-2,7,10H,3-6,8H2/p+2
6803-90-3Relevant articles and documents
2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
-
, (2008/06/13)
The present invention provides substituted dibenzoxazepine and dibenzthiazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, and for prostaglandin-E2 mediated diseases, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal, and a method for treating prostaglandin-E2 mediated diseases in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.
